{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:34:04Z","timestamp":1785443644008,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1140599"],"award-info":[{"award-number":["OPP1140599"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-11-LABX-0024-PARAFRAP"],"award-info":[{"award-number":["ANR-11-LABX-0024-PARAFRAP"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the currently recommended first- and second-line therapies for uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> infections in Equatorial Guinea. This study was designed to evaluate the efficacy of these artemisinin-based combinations and detect mutations in <jats:italic>P. falciparum kelch13<\/jats:italic>-propeller domain gene (<jats:italic>Pfkelch13<\/jats:italic>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-arm prospective study evaluating the efficacy of ASAQ and AL at three sites: Malabo, Bata and Ebebiyin was conducted between August 2017 and July 2018. Febrile children aged six months to 10\u00a0years with confirmed uncomplicated <jats:italic>P. falciparum<\/jats:italic> infection and other inclusion criteria were sequentially enrolled first in ASAQ and then in AL at each site, and followed up for 28\u00a0days.\u00a0Clinical and parasitological parameters were assessed. The primary endpoint was PCR-adjusted adequate clinical and parasitological response (ACPR). Samples on day-0 were analysed for mutations in <jats:italic>Pfkelch13<\/jats:italic> gene.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total 264 and 226 patients were enrolled in the ASAQ and AL treatment groups, respectively. Based on per-protocol analysis, PCR-adjusted cure rates of 98.6% to 100% and 92.4% to 100% were observed in patients treated with ASAQ and AL, respectively. All study children in both treatment groups were free of parasitaemia by day-3. Of the 476 samples with interpretable results, only three samples carried non-synonymous <jats:italic>Pfkelch13<\/jats:italic> mutations (E433D and A578S), and none of them is the known markers associated with artemisinin resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study confirmed high efficacy of ASAQ and AL for the treatment of uncomplicated falciparum infections as well as the absence of delayed parasite clearance and <jats:italic>Pfkelch13<\/jats:italic> mutations associated with artemisinin resistance. Continued monitoring of the efficacy of these artemisinin-based combinations, at least every two years, along with molecular markers associated with artemisinin and partner drug resistance is imperative to inform national malaria treatment policy and detect resistant parasites early.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ACTRN12617000456358, Registered 28 March 2017; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.anzctr.org.au\/trial\/MyTrial.aspx\">http:\/\/www.anzctr.org.au\/trial\/MyTrial.aspx<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03807-x","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:14:52Z","timestamp":1624364092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"actrn12617000456358","registry":"10.18810\/anzctr"}],"author":[{"given":"Matilde","family":"Riloha Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Mb\u00e1 Andeme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00f3n","family":"Nsue Esidang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Policarpo Ricardo","family":"Ncogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonder Philip","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Oki Eburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corona Eyang","family":"Ed\u00fa Maye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berzosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Katherine","family":"Lao Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spes Caritas","family":"Ntabangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Ringwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"3807_CR1","unstructured":"WHO. World Malaria Report 2020. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2020. Accessed 17 Feb 2021."},{"key":"3807_CR2","unstructured":"WHO. Antimalarial drug combination therapy: report of a WHO Technical Consultation. Geneva: World Health Organization; 2001."},{"key":"3807_CR3","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva: World Health Organization; 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240012813."},{"key":"3807_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"3807_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3807_CR6","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"3807_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670\u20139.","journal-title":"J Infect Dis"},{"key":"3807_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415\u201321.","journal-title":"Lancet Infect Dis"},{"key":"3807_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1473-3099(17)30048-8","volume":"17","author":"M Imwong","year":"2017","unstructured":"Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17:491\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3807_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","volume":"16","author":"NV Thanh","year":"2017","unstructured":"Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.","journal-title":"Malar J"},{"key":"3807_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3201\/eid2304.161872","volume":"23","author":"BQ Phuc","year":"2017","unstructured":"Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, M\u00e9nard D, et al. Treatment failure of dihydroartemisinin\/piperaquine for Plasmodium falciparum malaria. Vietnam Emerg Infect Dis. 2017;23:715\u20137.","journal-title":"Vietnam Emerg Infect Dis"},{"key":"3807_CR12","doi-asserted-by":"crossref","unstructured":"Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003\u20132013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784\u201391.","DOI":"10.1093\/cid\/ciw388"},{"key":"3807_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3807_CR14","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3807_CR15","unstructured":"Ministry of Health and Social Welfare, Equatorial Guinea. National Strategic Plan for Malaria Control Equatorial Guinea 2016\u20132020. National Malaria Control Programme, Ministry of Health and Social Welfare, Equatorial Guinea; 2016."},{"key":"3807_CR16","unstructured":"Ministry of Health and Social Welfare, Equatorial Guinea. National Theraputical Guide of Malaria. National Malaria Control Programme, Ministry of Health and Social Welfare, Equatorial Guinea; 2019."},{"key":"3807_CR17","unstructured":"Ministry of Health and Social Welfare, Equatorial Guinea. Evaluation of the efficacy of artesunate+amodiaquine in uncomplicated Plasmodium falciparum malaria (2010). National Programme of Malaria (Equatorial Guinea)\/National Centre of Tropical Medicine (ISCIII) (Spain), 2011."},{"key":"3807_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","volume":"13","author":"B Witkowski","year":"2013","unstructured":"Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13:1043\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3807_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"3807_CR20","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organisation; 2009. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/"},{"key":"3807_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4269\/ajtmh.2003.68.133","volume":"68","author":"A Cattamanchi","year":"2003","unstructured":"Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg. 2003;68:133\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3807_CR22","unstructured":"Medicines for Malaria Venture & WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29\u201331 May 2007, Amsterdam, The Netherlands. Geneva: World Health Organization; 2008. https:\/\/apps.who.int\/iris\/handle\/10665\/43824."},{"key":"3807_CR23","doi-asserted-by":"publisher","first-page":"e00590","DOI":"10.1128\/AAC.00590-19","volume":"63","author":"S Jones","year":"2019","unstructured":"Jones S, Kay K, Hodel EM, Chy S, Mbituyumuremyi A, Uwimana A, et al. Improving methods for analyzing antimalarial drug efficacy trials: molecular correction based on length-polymorphic markers msp-1, msp-2, and glurp. Antimicrob Agents Chemother. 2019;63:e00590-e619.","journal-title":"Antimicrob Agents Chemother"},{"key":"3807_CR24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4269\/ajtmh.12-0290","volume":"88","author":"P Charle","year":"2013","unstructured":"Charle P, Berzosa P, de Lucio A, Raso J, Nseng Nchama G, Benito A. Artesunate\/amodiaquine malaria treatment for Equatorial Guinea (Central Africa). Am J Trop Med Hyg. 2013;88:1087\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"3807_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","volume":"17","author":"E Davlantes","year":"2018","unstructured":"Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, F\u00e9lix J, et al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.","journal-title":"Malar J"},{"key":"3807_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2875-13-9","volume":"13","author":"D Djall\u00e9","year":"2014","unstructured":"Djall\u00e9 D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.","journal-title":"Malar J"},{"key":"3807_CR27","doi-asserted-by":"crossref","unstructured":"Ndounga M, Pembe Issamou Mayengue, Casimiro PN, Koukouikila-Koussounda F, Bitemo M, Diassivy Matondo B, et al. Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study. Malar J. 2015;14:423.","DOI":"10.1186\/s12936-015-0918-6"},{"key":"3807_CR28","first-page":"455","volume":"15","author":"M de Wit","year":"2016","unstructured":"de Wit M, Funk AL, Moussally K, Nkuba DA, Siddiqui R, Bil K, et al. In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu. Democratic Republic of Congo Malar J. 2016;15:455.","journal-title":"Democratic Republic of Congo Malar J"},{"key":"3807_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12936-019-3015-4","volume":"18","author":"BR Adegbite","year":"2019","unstructured":"Adegbite BR, Edoa JR, Honkpehedji YJ, Zinsou FJ, Dejon-Agobe JC, Mbong-Ngwese M, et al. Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambar\u00e9n\u00e9, Gabon: an open-label clinical trial. Malar J. 2019;18:424.","journal-title":"Malar J"},{"key":"3807_CR30","first-page":"1","volume":"1","author":"I Souleymane","year":"2017","unstructured":"Souleymane I, Cl\u00e9ment KH, Denis MM, Berenger A, Baba C, Offianan TA, et al. Therapeutic efficacy of artesunate-amodiaquine and polymorphism of Plasmodium falciparum k13-propeller gene in Pala (Tchad). Int J Open Access Trials. 2017;1:1\u20136.","journal-title":"Int J Open Access Trials"},{"key":"3807_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12936-019-2848-1","volume":"18","author":"B Abuaku","year":"2019","unstructured":"Abuaku B, Duah-Quashie NO, Quaye L, Matrevi SA, Quashie N, Gyasi A, et al. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015\u20132017. Malar J. 2019;18:206.","journal-title":"Malar J"},{"key":"3807_CR32","first-page":"49","volume":"64","author":"A Konat\u00e9","year":"2018","unstructured":"Konat\u00e9 A, Barro-Kiki PCM, Angora KE, B\u00e9dia-Tanoh AV, Djohan V, Kassi KF, et al. Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across C\u00f4te d\u2019Ivoire. Ann Parasitol. 2018;64:49\u201357.","journal-title":"Ann Parasitol"},{"key":"3807_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.4269\/ajtmh.18-0115","volume":"99","author":"JC Ebenebe","year":"2018","unstructured":"Ebenebe JC, Ntadom G, Ambe J, Wammanda R, Jiya N, Finomo F, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children ten years following adoption as first-line antimalarials. Am J Trop Med Hyg. 2018;99:649\u201364.","journal-title":"Am J Trop Med Hyg"},{"key":"3807_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12936-019-3089-z","volume":"19","author":"M Lingani","year":"2020","unstructured":"Lingani M, Bonkian LN, Yerbanga I, Kazienga A, Val\u00e9a I, Sorgho H, et al. In vivo\/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malar J. 2020;19:8.","journal-title":"Malar J"},{"key":"3807_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12936-018-2200-1","volume":"17","author":"F Grandesso","year":"2018","unstructured":"Grandesso F, Guindo O, Woi Messe L, Makarimi R, Traore A, Dama S, et al. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi. Niger Malar J. 2018;17:52.","journal-title":"Niger Malar J"},{"key":"3807_CR36","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1038\/s41598-020-65553-5","volume":"10","author":"MA Diallo","year":"2020","unstructured":"Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Sci Rep. 2020;10:8907.","journal-title":"Sci Rep"},{"key":"3807_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","volume":"17","author":"S Dama","year":"2018","unstructured":"Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar J. 2018;17:347.","journal-title":"Malar J"},{"key":"3807_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","volume":"213","author":"A Yeka","year":"2016","unstructured":"Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, et al. Artesunate\/amodiaquine versus artemether\/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis. 2016;213:1134\u201342.","journal-title":"J Infect Dis"},{"key":"3807_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12936-018-2340-3","volume":"17","author":"JM Roth","year":"2018","unstructured":"Roth JM, Sawa P, Makio N, Omweri G, Osoti V, Okach S, et al. Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. Malar J. 2018;17:199.","journal-title":"Malar J"},{"key":"3807_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","volume":"219","author":"A Yeka","year":"2019","unstructured":"Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis. 2019;219:1112\u201320.","journal-title":"J Infect Dis"},{"key":"3807_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/trstmh\/trz009","volume":"113","author":"A Uwimana","year":"2019","unstructured":"Uwimana A, Penkunas MJ, Nisingizwe MP, Warsame M, Umulisa N, Uyizeye D, et al. Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial. Trans R Soc Trop Med Hyg. 2019;113:312\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3807_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"3807_CR43","doi-asserted-by":"crossref","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS One. 2017;12:e0176004.","DOI":"10.1371\/journal.pone.0176004"},{"key":"3807_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231.","journal-title":"Malar J"},{"key":"3807_CR45","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12936-015-0986-7","volume":"14","author":"P Ncogo","year":"2015","unstructured":"Ncogo P, Herrador Z, Romay-Barja M, Garc\u00eda-Carrasco E, Nseng G, Berzosa P, et al. Malaria prevalence in Bata district, Equatorial Guinea: a cross-sectional study. Malar J. 2015;14:456.","journal-title":"Malar J"},{"key":"3807_CR46","doi-asserted-by":"crossref","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u2013843.","DOI":"10.4269\/ajtmh.14-0031"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03807-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03807-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:30:30Z","timestamp":1628613030000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03807-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3807"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03807-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ministry of Health and Social Welfare of Equatorial Guineas (No. 731\u2013150), the Ethics Committee of the Spanish National Health Institute, Carlos III (CEI PI 57_2016-v3), and the WHO Research Ethics Review Committee (ERC.000286). The parents or guardians of the study children provided written informed consent before enrolling their children in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}